Overview

Neoadjuvant Paclitaxel Versus BIBF 1120 Priming Followed by BIBF 1120 Plus Paclitaxel in Early HER-2 Negative Breast Cancer With Proteomic and Dynamic Imaging Correlates

Status:
Completed

Trial end date:
2014-04-01

Target enrollment:

Participant gender:

Summary

The investigators plan to study the efficacy of the combination of weekly paclitaxel + BIBF 1120 in early breast cancer using a neoadjuvant schedule and a randomized phase-II trial design, comparing the efficacy vs. weekly paclitaxel alone, followed by surgery and subsequent standards of care (anthracycline based chemotherapy, radiation or hormonal blockade).

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Centro Nacional de Investigaciones Oncologicas CARLOS III

Collaborators:

Grupo Espanol de Investigacion del Cancer de Mama
Hospital Universitari de Bellvitge
Hospital Universitario de Fuenlabrada
M.D. Anderson Cancer Center

Treatments:

Albumin-Bound Paclitaxel
Nintedanib
Paclitaxel